A Multicenter Randomized, Double Blind, Placebo- Controlled, Phase II Study to Compare Endocrine Treatment Alone Versus Endocrine Treatment With Everolimus in Patients With HR+/HER2- Metastatic Breast Cancer and Progression After Previous Treatment With Exemestane and Everolimus

Trial Profile

A Multicenter Randomized, Double Blind, Placebo- Controlled, Phase II Study to Compare Endocrine Treatment Alone Versus Endocrine Treatment With Everolimus in Patients With HR+/HER2- Metastatic Breast Cancer and Progression After Previous Treatment With Exemestane and Everolimus

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2016

At a glance

  • Drugs Everolimus (Primary) ; Hormone modulators
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms Evelyn
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 16 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top